KLOW80 (80mg*10vials)

KLOW80 (80mg): A Proprietary Multi-Peptide Blend Formulation Combining Eight Distinct Active Peptide Components — Including CJC-1295 (without DAC), Ipamorelin, BPC-157, TB-500 (Thymosin Beta-4 Fragment), Epithalon, DSIP, Selank, and Semax — in a Single 80mg Lyophilized Vial for Investigational Research in Muscle Hypertrophy, Fat Loss, Recovery, Tissue Repair, Anti-Aging, Sleep Optimization, Cognitive Enhancement, and Overall Metabolic Health

KLOW80 is a proprietary, custom-formulated multi-peptide blend that combines eight distinct, well-researched peptide components into a single 80mg lyophilized vial, designed for investigational research in multiple physiological and metabolic pathways simultaneously. The KLOW80 formulation includes the following eight peptide components, each selected for its specific biological activity and potential synergistic interactions with the other components in the blend: (1) CJC-1295 (without DAC) — a tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH) that stimulates growth hormone (GH) release from the pituitary gland by binding to and activating the GHRH receptor (GHRHR) on somatotrophs; CJC-1295 without DAC (drug affinity complex) has a shorter half-life (~30 minutes) than CJC-1295 with DAC (~8-10 days), making it more suitable for pulsatile GH release protocols that mimic physiological GH secretion patterns; (2) Ipamorelin — a selective pentapeptide growth hormone secretagogue (GHS) and ghrelin receptor (GHS-R1a) agonist that stimulates GH release with high selectivity for GH over other pituitary hormones (prolactin, ACTH, cortisol), making it one of the most targeted and well-tolerated GHS compounds; (3) BPC-157 (Body Protection Compound-157) — a 15-amino-acid peptide derived from a protective protein found in human gastric juice, with well-documented tissue repair, wound healing, and cytoprotective effects, promoting the healing of tendons, ligaments, muscles, bones, and the gastrointestinal tract; (4) TB-500 (Thymosin Beta-4 fragment, specifically the N-terminal 1-4 fragment or the active 17-23 fragment [LKKTETQ]) — a synthetic peptide fragment of thymosin beta-4 (a 43-amino-acid peptide involved in tissue repair, cell migration, angiogenesis, and inflammation regulation), with TB-500 being the commercially available synthetic fragment that captures the key active region of thymosin beta-4; (5) Epithalon (Epitalon, Epithalon) — a synthetic tetrapeptide (Ala-Glu-Asp-Gly) analog of the pineal gland peptide epithalamin, with telomere-lengthening (via telomerase activation), antioxidant, and anti-aging effects, originally developed by the Russian gerontologist Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology; (6) DSIP (Delta Sleep-Inducing Peptide) — a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit cerebral venous blood during slow-wave sleep, with sleep-promoting, stress-reducing, neuroprotective, and metabolic regulatory effects; (7) Selank — a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) analog of the endogenous immunomodulatory peptide tuftsin, developed in Russia, with anxiolytic (anti-anxiety), nootropic (cognitive-enhancing), neuroprotective, and immunomodulatory effects; and (8) Semax — a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) analog of the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), developed in Russia, with nootropic (cognitive-enhancing), neuroprotective, anxiolytic, and anti-inflammatory effects. The KLOW80 formulation combines these eight peptide components into a single 80mg vial, with each component present at a specific dose designed to provide a balanced, multi-pathway physiological effect profile. The exact dosing ratio of each component in the KLOW80 blend is proprietary, but the formulation is designed to provide meaningful, research-relevant doses of each component when the full 80mg vial is reconstituted and administered according to typical research protocols. The rationale for combining these eight specific peptide components into a single formulation is based on the concept of multi-pathway synergism — the idea that combining peptides with complementary, non-overlapping mechanisms of action can produce broader, more comprehensive physiological effects than any single peptide alone, and that the components may work synergistically to enhance each other's effects. Specifically, the KLOW80 formulation covers the following key physiological pathways: (1) Growth hormone / IGF-1 axis stimulation (via CJC-1295 [GHRH analog] + Ipamorelin [GHS/ghrelin receptor agonist] — these two work synergistically, with CJC-1295 stimulating GHRH receptors and Ipamorelin stimulating GHS-R1a receptors, both converging on increased GH release from pituitary somatotrophs, producing a more robust GH response than either alone — this is the well-known "GHRH + GHS synergy" that is the basis of many popular peptide protocols like "CJC-1295 + Ipamorelin" or "Mod GRF + GHRP-2"); (2) Tissue repair and recovery (via BPC-157 + TB-500 — these two tissue repair peptides work through complementary mechanisms, with BPC-157 primarily promoting tendon/ligament/muscle/bone healing and gastrointestinal protection, and TB-500 primarily promoting cell migration, angiogenesis, and inflammation resolution, together providing comprehensive tissue repair and recovery support); (3) Anti-aging and cellular health (via Epithalon — telomerase activation, telomere lengthening, antioxidant effects, and pineal gland regulation, providing a distinct anti-aging/longevity pathway that complements the anabolic and repair pathways); (4) Sleep optimization and stress reduction (via DSIP — delta sleep-inducing peptide promotes slow-wave sleep, reduces stress hormones [cortisol], and provides neuroprotection, supporting recovery and overall physiological balance); (5) Cognitive enhancement and mood regulation (via Selank + Semax — these two Russian-developed nootropic peptides work through complementary mechanisms, with Selank primarily providing anxiolytic [anti-anxiety] and immunomodulatory effects, and Semax primarily providing cognitive enhancement [memory, focus, mental clarity] and neuroprotective effects, together supporting cognitive function, mood, and mental well-being). By combining all eight components into a single formulation, KLOW80 aims to provide a comprehensive, multi-system physiological effect profile that covers anabolic (muscle growth), metabolic (fat loss), reparative (tissue healing), anti-aging (telomere/cellular), sleep (recovery), and cognitive (mental performance) pathways simultaneously — potentially offering a more complete "overall health and performance" profile than any single peptide or simpler combination. The 80mg vial format provides a convenient, single-vial delivery system for this multi-component blend, eliminating the need for researchers to mix multiple individual peptide vials. The KLOW80 formulation is designed for investigational research use only, and the specific dosing, administration protocols, and physiological effects should be determined by the researcher based on the research objectives and the available scientific literature on each individual component. It is important to note that KLOW80 is a proprietary blend formulation, and the long-term safety, efficacy, and optimal dosing of this specific eight-component combination have not been extensively studied in human clinical trials — the effects of the blend are inferred from the known effects of each individual component and from the well-documented synergies between certain pairs (e.g., CJC-1295 + Ipamorelin, BPC-157 + TB-500), but the specific effects of the full eight-component combination may differ from the simple sum of individual component effects due to potential interactions (both synergistic and antagonistic) between the components. Researchers using KLOW80 should carefully review the scientific literature on each individual component, consider potential interactions, and start with conservative dosing to assess individual tolerance and response^{[1][2][3][4][5][6][7][8][9][10]}.

The Eight Components of KLOW80: A Detailed Analysis of Each Peptide, Its Mechanism of Action, and Its Role in the Blend

1. CJC-1295 (without DAC) — Growth Hormone-Releasing Hormone (GHRH) Analog for Pulsatile GH Release: CJC-1295 (also known as CJC-1295 no-DAC, or modified GRF 1-29 [tetrasubstituted] — it is essentially a modified version of the first 29 amino acids of human GHRH, with four amino acid substitutions [Ala→Gln at position 8, Gly→Ala at position 15, Ala→Leu at position 27, and the addition of a non-standard amino acid or modification at the C-terminus] that confer proteolytic resistance and extend half-life compared to native GHRH or the unmodified GRF 1-29 [Sermorelin]). CJC-1295 without DAC has a half-life of approximately 30 minutes (compared to ~8-10 days for CJC-1295 with DAC, which forms a drug affinity complex with albumin via a maleimide linker), making it more suitable for pulsatile GH release protocols that mimic the physiological pattern of GH secretion (which is naturally pulsatile, primarily at night during deep sleep). CJC-1295 works by binding to and activating the GHRH receptor (GHRHR) — a G protein-coupled receptor (GPCR) of the class B (secretin-like) family, expressed on pituitary somatotrophs (GH-producing cells). GHRHR activation stimulates the Gs/cAMP/PKA signaling pathway, leading to increased GH synthesis and release from somatotrophs. In the KLOW80 blend, CJC-1295 provides the GHRH receptor stimulation component of GH axis activation, working synergistically with Ipamorelin (which provides the GHS-R1a/ghrelin receptor stimulation component) — the combination of GHRH analog + GHS is well-known to produce a more robust GH response than either alone, because they activate two distinct, complementary receptor pathways that converge on GH release from somatotrophs (this is the basis of the popular "CJC-1295 + Ipamorelin" or "Mod GRF + GHRP" protocols used in peptide research). CJC-1295 without DAC is preferred over CJC-1295 with DAC in the KLOW80 formulation because the shorter half-life allows for more physiological, pulsatile GH release (rather than continuous, non-physiological GH elevation, which may be associated with more side effects like insulin resistance, edema, and potential desensitization).
2. Ipamorelin — Selective Growth Hormone Secretagogue (GHS) and Ghrelin Receptor (GHS-R1a) Agonist: Ipamorelin (developmental code name NNC 26-0161) is a synthetic pentapeptide (5-amino-acid peptide) with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (where Aib = α-aminoisobutyric acid, a non-proteinogenic amino acid conferring proteolytic resistance; D-2-Nal = D-2-naphthylalanine; D-Phe = D-phenylalanine; and the C-terminus is amidated [-NH2]). It has a molecular weight of approximately 711.9 Daltons. Ipamorelin was developed by Novo Nordisk as a third-generation growth hormone secretagogue (GHS), specifically designed for high selectivity for growth hormone (GH) release with minimal effects on other pituitary hormones — particularly prolactin (PRL), adrenocorticotropic hormone (ACTH), and cortisol. This selectivity distinguishes ipamorelin from earlier GHS compounds like GHRP-2, GHRP-6, and hexarelin, which can significantly elevate prolactin, ACTH, and cortisol (particularly at higher doses), leading to side effects like gynecomastia (from prolactin elevation) and catabolic/immunosuppressive effects (from cortisol elevation). Ipamorelin works by binding to and activating the growth hormone secretagogue receptor 1a (GHS-R1a, also known as the ghrelin receptor — the endogenous receptor for the gastric hormone ghrelin, the "hunger hormone") — a GPCR of the class A family, primarily coupled to Gq/11 signaling, expressed on pituitary somatotrophs and hypothalamic GHRH/NPY neurons. GHS-R1a activation stimulates the Gq/PLC/IP3/Ca2+ signaling pathway, leading to increased intracellular calcium in somatotrophs and subsequent GH release. In the KLOW80 blend, ipamorelin provides the GHS-R1a/ghrelin receptor stimulation component of GH axis activation, working synergistically with CJC-1295 (GHRH receptor stimulation) to produce a robust, pulsatile GH response. The high selectivity of ipamorelin (minimal prolactin/ACTH/cortisol effects) makes it a particularly favorable choice for a multi-component blend, as it minimizes the risk of hormonal side effects that could be exacerbated by the other components in the formulation.
3. BPC-157 (Body Protection Compound-157) — Tissue Repair, Wound Healing, and Cytoprotective Peptide: BPC-157 is a 15-amino-acid synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), derived from a protective protein (BPC, Body Protection Compound) found in human gastric juice. It has a molecular weight of approximately 1,419 Daltons. BPC-157 was originally discovered and extensively studied by Croatian researchers (primarily at the University of Zagreb and the Pliva pharmaceutical company), who demonstrated its remarkable tissue repair and cytoprotective effects in numerous preclinical studies. BPC-157 has been shown to promote the healing of a wide variety of tissues, including: tendons and ligaments (tendon-to-bone healing, ligament repair), muscles (muscle strain and tear repair), bones (fracture healing, bone regeneration), skin (wound healing, burn repair), the gastrointestinal tract (gastric and duodenal ulcer healing, inflammatory bowel disease protection, fistula healing), the liver (liver injury repair, fibrosis protection), the heart (myocardial infarction protection, heart repair), the brain (neuroprotection, stroke recovery), and the cornea (corneal wound healing). The mechanisms of action of BPC-157 are complex and not fully elucidated, but appear to involve: (1) promotion of angiogenesis (new blood vessel formation) via upregulation of VEGF and other angiogenic factors; (2) promotion of fibroblast and tenocyte migration and proliferation; (3) modulation of growth factor expression (TGF-β, FGF, PDGF, EGF); (4) anti-inflammatory effects (modulation of cytokines, inhibition of NF-κB); (5) cytoprotective effects (protection of cells from oxidative stress, toxins, and injury); (6) modulation of the nitric oxide (NO) system; and (7) potential effects on the gut-brain axis and the dopaminergic system. In the KLOW80 blend, BPC-157 provides the primary tissue repair and recovery component, working in conjunction with TB-500 (which provides complementary tissue repair and cell migration effects) to support comprehensive tissue healing and recovery — particularly relevant for researchers studying muscle/tendon/ligament repair, post-workout recovery, injury rehabilitation, and gastrointestinal health. BPC-157 is generally considered to have a very favorable safety profile in preclinical studies, with minimal reported side effects even at high doses.
4. TB-500 (Thymosin Beta-4 Fragment) — Cell Migration, Angiogenesis, and Tissue Repair Peptide: TB-500 is a synthetic peptide fragment of thymosin beta-4 (Tβ4), a 43-amino-acid peptide that is the major actin-sequestering protein in mammalian cells, involved in cell migration, cell differentiation, angiogenesis (new blood vessel formation), tissue repair, and inflammation regulation. TB-500 specifically refers to the commercially available synthetic fragment of thymosin beta-4 that contains the key active region — most commonly the N-terminal 1-4 fragment (Ac-Ser-Asp-Lys-Pro, also known as AcSDKP, a naturally occurring fragment with antifibrotic and hematopoietic effects) or the 17-23 fragment (LKKTETQ, the actin-binding domain of thymosin beta-4, which is responsible for many of its tissue repair and cell migration effects). The exact composition of "TB-500" can vary between manufacturers, but it generally refers to a synthetic peptide fragment that captures the key active region(s) of thymosin beta-4 responsible for its tissue repair, cell migration, and angiogenic effects. Thymosin beta-4 (and its active fragments like TB-500) works through several mechanisms: (1) actin sequestration and regulation — thymosin beta-4 binds to G-actin (globular actin) and regulates actin polymerization/depolymerization, which is essential for cell migration, cell shape changes, and tissue remodeling; (2) promotion of cell migration — thymosin beta-4 promotes the migration of multiple cell types (endothelial cells, fibroblasts, keratinocytes, stem cells) to sites of tissue injury, which is essential for wound healing and tissue repair; (3) promotion of angiogenesis — thymosin beta-4 stimulates new blood vessel formation (angiogenesis) by promoting endothelial cell migration and differentiation, which is critical for delivering oxygen and nutrients to healing tissues; (4) anti-inflammatory effects — thymosin beta-4 modulates inflammation by reducing pro-inflammatory cytokines and promoting anti-inflammatory factors; (5) inhibition of scar formation/fibrosis — thymosin beta-4 (and its AcSDKP fragment) has antifibrotic effects, reducing excessive scar tissue formation and promoting more regenerative healing; (6) cardioprotective and neuroprotective effects — thymosin beta-4 has been shown to protect the heart and brain from ischemic injury. In the KLOW80 blend, TB-500 provides a complementary tissue repair component to BPC-157: while BPC-157 is particularly strong in tendon/ligament/muscle/bone healing and gastrointestinal protection, TB-500 is particularly strong in cell migration, angiogenesis, and inflammation resolution — together they provide a more comprehensive tissue repair and recovery profile than either alone. The combination of BPC-157 + TB-500 is one of the most popular and well-documented peptide combinations for tissue repair and injury recovery in peptide research.
5. Epithalon (Epitalon, Epithalon) — Telomerase-Activating, Anti-Aging Tetrapeptide: Epithalon (also known as Epitalon, Epithalon, or Epithalamin) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), developed by the Russian gerontologist Professor Vladimir Khavinson and his colleagues at the St. Petersburg Institute of Bioregulation and Gerontology over several decades of research. Epithalon is a synthetic analog of epithalamin, a peptide bioregulator originally isolated from the pineal gland (epiphysis) of young calves, which was found to have potent anti-aging and pineal gland-regulating effects. Epithalon has a molecular weight of approximately 395 Daltons (very small, only 4 amino acids). The primary and most well-known mechanism of action of epithalon is its ability to activate telomerase — the enzyme that adds telomeric DNA repeats (TTAGGG) to the ends of chromosomes, thereby lengthening telomeres. Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division, and telomere shortening is considered one of the primary hallmarks of aging (the "telomere theory of aging"). By activating telomerase, epithalon can potentially slow or reverse telomere shortening, which has been associated with extended cellular lifespan and potential anti-aging effects. In a landmark study, Khavinson and colleagues demonstrated that epithalon can activate telomerase in human somatic cells and extend their replicative lifespan, and long-term studies in animals showed that epithalon administration increased mean and maximum lifespan by up to 25-30% in mice and rats, and reduced age-related pathology and tumor incidence. In addition to telomerase activation, epithalon has several other mechanisms of action: (1) antioxidant effects — epithalon increases the activity of antioxidant enzymes (superoxide dismutase [SOD], catalase, glutathione peroxidase) and reduces oxidative stress; (2) pineal gland regulation — epithalon regulates pineal gland function and melatonin secretion, which is important for circadian rhythm regulation, sleep, and overall endocrine health; (3) immunomodulatory effects — epithalon modulates immune function, improving age-related immune decline (immunosenescence); (4) gene expression regulation — epithalon regulates the expression of multiple genes involved in aging, metabolism, and cellular function; (5) neuroprotective effects — epithalon has been shown to protect neurons from age-related degeneration and improve cognitive function in aged animals; (6) metabolic effects — epithalon may improve glucose metabolism and lipid profiles in aged animals. In the KLOW80 blend, epithalon provides the primary anti-aging/longevity component, offering a distinct pathway (telomerase activation, telomere lengthening, antioxidant, pineal regulation) that complements the anabolic (CJC-1295 + Ipamorelin), reparative (BPC-157 + TB-500), sleep (DSIP), and cognitive (Selank + Semax) components. The inclusion of epithalon in the blend reflects the concept of "comprehensive anti-aging" — addressing multiple hallmarks of aging simultaneously (telomere attrition, oxidative stress, immune senescence, pineal decline) alongside the performance and recovery benefits of the other components. Epithalon is generally considered to have a very favorable safety profile, with minimal reported side effects in preclinical and early clinical studies (it is a very small, naturally-derived peptide with low immunogenicity).
6. DSIP (Delta Sleep-Inducing Peptide) — Sleep-Promoting, Stress-Reducing, Neuroprotective Nonapeptide: DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (9-amino-acid peptide) with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDSAG E), originally discovered in 1974 by Swiss researchers (Schoenenberger and Monnier) who isolated it from the cerebral venous blood of rabbits during slow-wave (delta) sleep — hence its name "delta sleep-inducing peptide." DSIP has a molecular weight of approximately 848.9 Daltons. As its name suggests, the primary and most well-known effect of DSIP is its ability to promote and enhance delta (slow-wave) sleep — the deep, restorative stage of sleep associated with physical recovery, growth hormone release (GH is primarily released during deep sleep), memory consolidation, and overall physiological restoration. DSIP works through several mechanisms: (1) promotion of delta sleep — DSIP increases the duration and quality of slow-wave (delta) sleep, which is the most restorative stage of sleep and the stage during which the majority of growth hormone is released; (2) stress reduction and cortisol modulation — DSIP has been shown to reduce stress responses and lower elevated cortisol levels (the "stress hormone"), which is important because chronic stress and elevated cortisol are catabolic (muscle-breaking), immunosuppressive, and detrimental to recovery and overall health; (3) neuroprotective effects — DSIP protects neurons from oxidative stress, excitotoxicity, and ischemic injury, and may have potential applications in neurodegenerative disease research; (4) metabolic regulatory effects — DSIP has been shown to modulate glucose metabolism, reduce blood pressure, and regulate body temperature; (5) analgesic (pain-relieving) effects — DSIP has mild analgesic properties; (6) anticonvulsant effects — DSIP has been shown to have anticonvulsant properties in some seizure models; (7) potential effects on the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-gonadal (HPG) axis. In the KLOW80 blend, DSIP provides the sleep optimization and stress reduction component — supporting deep, restorative sleep (which is essential for recovery, muscle growth [via GH release during deep sleep], and overall physiological balance) and reducing stress/cortisol (which counteracts the catabolic effects of stress and supports an anabolic environment). The inclusion of DSIP in a multi-component performance/recovery blend is particularly logical because: (a) deep sleep is the primary time of endogenous GH release, so DSIP's sleep-promoting effects may synergize with the GH-stimulating effects of CJC-1295 + Ipamorelin; (b) stress reduction and cortisol lowering create a more favorable anabolic environment for muscle growth and recovery; (c) improved sleep quality supports cognitive function, mood, and overall well-being — complementing the nootropic effects of Selank + Semax. DSIP is generally considered to have a favorable safety profile, with minimal reported side effects (it is a naturally occurring peptide with low toxicity).
7. Selank — Anxiolytic (Anti-Anxiety), Nootropic, Neuroprotective, Immunomodulatory Heptapeptide: Selank is a synthetic heptapeptide (7-amino-acid peptide) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), developed in Russia by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences and the V. Zakusov Research Institute of Pharmacology. Selank is an analog of the endogenous immunomodulatory peptide tuftsin (a tetrapeptide with the sequence Thr-Lys-Pro-Arg [TKPR], naturally produced in the spleen and involved in immune function), with the addition of three C-terminal amino acids (Pro-Gly-Pro) that confer proteolytic resistance, extend half-life, and enhance biological activity. Selank has a molecular weight of approximately 751.9 Daltons. Selank has multiple mechanisms of action and biological effects: (1) Anxiolytic (anti-anxiety) effects — Selank is perhaps best known for its potent anxiolytic effects, which have been demonstrated in numerous preclinical and clinical studies in Russia. Unlike benzodiazepines (the traditional anti-anxiety medications), Selank does not cause sedation, drowsiness, cognitive impairment, dependence, or withdrawal — it is considered a "non-sedating anxiolytic" that reduces anxiety while maintaining or even enhancing cognitive function. The anxiolytic effects of Selank appear to involve modulation of the serotonergic and GABAergic systems, as well as effects on the hypothalamic-pituitary-adrenal (HPA) axis (reducing stress-induced cortisol elevation); (2) Nootropic (cognitive-enhancing) effects — Selank has been shown to enhance cognitive function, including memory, learning, attention, and mental clarity, particularly under conditions of stress or cognitive impairment. It appears to work by modulating neurotransmitter systems (serotonin, dopamine, GABA), increasing brain-derived neurotrophic factor (BDNF) expression, and improving neuronal plasticity; (3) Neuroprotective effects — Selank protects neurons from oxidative stress, excitotoxicity, and ischemic injury, and may have potential applications in neurodegenerative disease research (Alzheimer's, Parkinson's) and stroke recovery; (4) Immunomodulatory effects — as an analog of tuftsin (an immunomodulatory peptide), Selank modulates immune function, enhancing immune responses when they are suppressed and normalizing them when they are overactive (immunomodulation rather than simple immunosuppression or immunostimulation); (5) Antioxidant effects — Selank reduces oxidative stress and increases antioxidant enzyme activity; (6) Metabolic effects — Selank may have beneficial effects on glucose metabolism and lipid profiles. In the KLOW80 blend, Selank provides the primary anxiolytic (anti-anxiety) and immunomodulatory component, working in conjunction with Semax (which provides complementary cognitive-enhancing and neuroprotective effects) to support cognitive function, mood, and mental well-being. The inclusion of Selank in a performance/recovery blend is valuable because: (a) anxiety and stress are catabolic (via cortisol elevation) and detrimental to performance, recovery, and overall health — Selank's anxiolytic effects create a more favorable mental and physiological state; (b) cognitive function and mental clarity are important for training focus, motivation, and overall quality of life; (c) immunomodulatory effects support overall immune health, particularly important during periods of intense training or stress (which can suppress immune function). Selank is generally considered to have a very favorable safety profile, with minimal reported side effects (no sedation, no dependence, no cognitive impairment — unlike traditional anti-anxiety medications).
8. Semax — Nootropic (Cognitive-Enhancing), Neuroprotective, Anxiolytic Heptapeptide: Semax is a synthetic heptapeptide (7-amino-acid peptide) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), developed in Russia by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences (the same institute that developed Selank — Semax was developed slightly earlier, in the 1980s-1990s). Semax is an analog of the N-terminal fragment of adrenocorticotropic hormone (ACTH), specifically ACTH 4-10 (the sequence Met-Glu-His-Phe-Arg-Trp-Gly, which is the minimal fragment of ACTH that retains nootropic/neurotrophic effects without the hormonal [ACTH/corticosteroid-stimulating] effects of full-length ACTH), with the substitutions of Pro for Arg at position 5 and Pro for Trp at position 6, and the addition of a C-terminal Pro (making it a heptapeptide rather than the 7-amino-acid ACTH 4-10 — actually Semax is 7 amino acids: Met-Glu-His-Phe-Pro-Gly-Pro, while ACTH 4-10 is Met-Glu-His-Phe-Arg-Trp-Gly, also 7 amino acids, with Semax having Pro substitutions at positions 5 and 6 and a different C-terminus). These modifications confer proteolytic resistance, extend half-life, and enhance nootropic activity while eliminating the hormonal effects of ACTH. Semax has a molecular weight of approximately 854.0 Daltons. Semax has multiple mechanisms of action and biological effects: (1) Nootropic (cognitive-enhancing) effects — Semax is perhaps best known for its potent nootropic effects, which have been extensively studied in Russia (where it is an approved medication for cognitive impairment, stroke recovery, and attention disorders) and demonstrated in numerous preclinical and clinical studies. Semax enhances multiple aspects of cognitive function, including: memory (short-term and long-term, working memory), learning and memory formation, attention and focus, mental clarity and "brain fog" reduction, executive function, and information processing speed. It appears to work by: modulating neurotransmitter systems (dopamine, serotonin, norepinephrine, acetylcholine — Semax has been shown to increase dopamine and serotonin turnover in specific brain regions, and to modulate cholinergic function); increasing the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — neurotrophic factors that support neuronal survival, growth, and plasticity; improving cerebral blood flow and brain energy metabolism (glucose utilization, ATP production); and enhancing neuronal plasticity and synapse formation; (2) Neuroprotective effects — Semax has potent neuroprotective effects, protecting neurons from oxidative stress, excitotoxicity (glutamate-induced neuronal damage), ischemic injury (stroke), and neurotoxic insults. It has been shown to reduce infarct size and improve functional recovery in animal models of stroke, and is used clinically in Russia for stroke recovery and traumatic brain injury. The neuroprotective mechanisms include: antioxidant effects (reducing reactive oxygen species [ROS], increasing antioxidant enzymes); anti-excitotoxic effects (modulating glutamate receptor activity, reducing calcium overload); anti-inflammatory effects (reducing neuroinflammation, microglial activation); and upregulation of neurotrophic factors (BDNF, NGF) that support neuronal survival; (3) Anxiolytic (anti-anxiety) effects — although Semax is primarily known as a nootropic, it also has mild to moderate anxiolytic effects, reducing anxiety and stress responses without causing sedation. This appears to involve modulation of the serotonergic system and the HPA axis (reducing stress-induced cortisol elevation); (4) Anti-inflammatory effects — Semax reduces inflammation in the brain (neuroinflammation) and potentially in peripheral tissues, by modulating cytokine expression and immune cell activity; (5) Analgesic (pain-relieving) effects — Semax has mild analgesic properties, possibly through modulation of pain pathways in the brain and spinal cord; (6) Metabolic effects — Semax may improve brain energy metabolism and glucose utilization, and may have peripheral metabolic effects as well. In the KLOW80 blend, Semax provides the primary cognitive-enhancing (nootropic) and neuroprotective component, working in conjunction with Selank (which provides complementary anxiolytic and immunomodulatory effects) to support cognitive function, mental clarity, focus, memory, and overall brain health. The combination of Selank + Semax is a popular and well-documented nootropic peptide combination in Russian peptide research, with the two peptides working through complementary mechanisms (Selank = more anxiolytic/immunomodulatory, Semax = more cognitive-enhancing/neuroprotective) to provide comprehensive cognitive and mental health support. The inclusion of nootropic peptides in a multi-component performance/recovery blend is valuable because: (a) cognitive function, focus, and mental clarity are important for training motivation, adherence, and overall quality of life; (b) neuroprotective effects support long-term brain health, particularly relevant for individuals engaging in intense physical training (which can involve head impacts, oxidative stress, and systemic inflammation that may affect the brain); (c) anxiolytic effects (from both Selank and Semax) reduce stress and cortisol, creating a more favorable anabolic environment; (d) improved sleep (from DSIP) combined with cognitive enhancement (from Selank + Semax) supports overall mental and physical recovery. Semax is generally considered to have a very favorable safety profile, with minimal reported side effects (it is a modified ACTH fragment with no hormonal [ACTH/corticosteroid] effects, no sedation, no dependence — unlike many cognitive-enhancing medications like stimulants)^{[1][2][3][4][5][6][7][8][9][10]}.

The Rationale for the KLOW80 Multi-Peptide Blend: Synergism, Complementary Mechanisms, and Comprehensive Physiological Coverage

The KLOW80 formulation is based on the principle of multi-pathway synergism — the idea that combining peptides with complementary, non-overlapping mechanisms of action can produce broader, more comprehensive physiological effects than any single peptide alone, and that certain peptide combinations may produce synergistic effects (where the combined effect is greater than the simple sum of individual effects). The eight components of KLOW80 were specifically selected to cover six distinct, complementary physiological pathways, with several well-documented synergistic pairs built into the formulation:

Synergistic Pair 1: CJC-1295 (GHRH analog) + Ipamorelin (GHS/ghrelin receptor agonist) — Growth Hormone Axis Synergy. This is perhaps the most well-documented and widely used synergistic peptide combination in peptide research. CJC-1295 (a GHRH analog) stimulates the GHRH receptor (GHRHR) on pituitary somatotrophs, while Ipamorelin (a GHS) stimulates the ghrelin receptor (GHS-R1a) on the same somatotrophs. These two receptors activate distinct but complementary intracellular signaling pathways (GHRHR → Gs/cAMP/PKA; GHS-R1a → Gq/PLC/IP3/Ca2+), and when both are activated simultaneously, they produce a synergistic increase in GH release that is significantly greater than the sum of either peptide alone. This synergy is well-documented in the scientific literature and is the basis of the popular "CJC-1295 + Ipamorelin" or "Mod GRF + GHRP" protocols used by peptide researchers. By including both CJC-1295 and Ipamorelin in the KLOW80 blend, the formulation leverages this well-established synergy to produce a robust GH response — and because both components are present in a single vial, the researcher does not need to mix two separate vials. The use of CJC-1295 without DAC (rather than with DAC) is intentional: the shorter half-life (~30 min) allows for more physiological, pulsatile GH release (mimicking the natural pulsatile pattern of GH secretion, primarily at night), which is considered more physiological and potentially safer than the continuous, non-physiological GH elevation produced by CJC-1295 with DAC (half-life ~8-10 days). The use of Ipamorelin (rather than GHRP-2, GHRP-6, or hexarelin) is also intentional: Ipamorelin is the most selective GHS for GH release, with minimal effects on prolactin, ACTH, and cortisol — minimizing the risk of hormonal side effects that could be exacerbated by the other components in the blend.

Synergistic Pair 2: BPC-157 + TB-500 — Tissue Repair and Recovery Synergy. This is another well-documented and popular synergistic peptide combination. BPC-157 and TB-500 both promote tissue repair and wound healing, but they work through complementary mechanisms and have somewhat different tissue specificities: BPC-157 is particularly strong in tendon/ligament healing (tendon-to-bone healing), muscle repair, bone fracture healing, and gastrointestinal protection (gastric/duodenal ulcer healing, inflammatory bowel disease), working through mechanisms that include promotion of angiogenesis, fibroblast/tenocyte migration, growth factor modulation (TGF-β, FGF, VEGF), anti-inflammatory effects, and cytoprotection. TB-500 (a fragment of thymosin beta-4) is particularly strong in cell migration (endothelial cells, fibroblasts, keratinocytes, stem cells), angiogenesis (new blood vessel formation), inflammation resolution, and antifibrotic (anti-scar) effects, working primarily through actin sequestration/regulation (which is essential for cell migration and shape changes), promotion of endothelial cell migration and angiogenesis, and modulation of inflammation and fibrosis. When used together, BPC-157 + TB-500 provide comprehensive tissue repair coverage — BPC-157 provides the "healing stimulus" (particularly for tendons, ligaments, muscles, bones, and GI tract), while TB-500 provides the "cell migration and angiogenesis" support that delivers cells and nutrients to the healing site and resolves inflammation. This combination is one of the most popular peptide protocols for injury recovery, post-workout recovery, and tissue repair in peptide research. By including both BPC-157 and TB-500 in the KLOW80 blend, the formulation leverages this complementary tissue repair synergy to support comprehensive recovery — particularly relevant for researchers studying muscle/tendon/ligament injury, post-training recovery, and overall tissue health.

Synergistic Pair 3: DSIP (sleep) + CJC-1295/Ipamorelin (GH) — Sleep-GH Synergy. A less commonly discussed but physiologically important synergy exists between DSIP (delta sleep-inducing peptide) and the GH-stimulating components (CJC-1295 + Ipamorelin). Growth hormone (GH) is primarily released in pulses during deep (delta) sleep — approximately 70-80% of daily GH secretion occurs during the first few hours of deep sleep, particularly during slow-wave (delta) sleep stages. DSIP specifically promotes and enhances delta (slow-wave) sleep, which is the stage of sleep during which the majority of GH is released. Therefore, by promoting deep sleep, DSIP may synergize with the GH-stimulating effects of CJC-1295 + Ipamorelin — creating a more favorable physiological environment for GH release (both endogenous and pharmacologically stimulated). Additionally, DSIP reduces stress and cortisol (the "stress hormone," which is catabolic [muscle-breaking] and antagonistic to GH release), further supporting an anabolic environment. This sleep-GH synergy is a key rationale for including DSIP in a multi-component anabolic/recovery blend like KLOW80 — it supports the very physiological state (deep sleep) during which the anabolic effects of GH are most prominent.

Synergistic Pair 4: Selank + Semax — Nootropic/Cognitive Synergy. Selank and Semax are both Russian-developed nootropic peptides, but they have complementary profiles: Selank is primarily anxiolytic (anti-anxiety) and immunomodulatory, with secondary nootropic effects; Semax is primarily nootropic (cognitive-enhancing, memory, focus, mental clarity) and neuroprotective, with secondary anxiolytic effects. When used together, Selank + Semax provide comprehensive cognitive and mental health coverage — Selank reduces anxiety and stress (creating a calm, focused mental state), while Semax enhances cognitive function, memory, and mental clarity (providing the "mental performance" component). This combination is popular in Russian peptide research for cognitive enhancement, stress reduction, and overall mental performance. By including both Selank and Semax in the KLOW80 blend, the formulation provides comprehensive cognitive support — reducing anxiety/stress (which is catabolic via cortisol and detrimental to performance) while enhancing focus, memory, and mental clarity (which supports training motivation, adherence, and overall quality of life).

Distinct Pathway: Epithalon (Anti-Aging/Telomerase). Epithalon provides a distinct, non-overlapping pathway that is not covered by any other component in the KLOW80 blend: telomerase activation and telomere lengthening (the "telomere theory of aging"), plus antioxidant, pineal gland-regulating, and immunomodulatory effects. While the other components primarily address performance (anabolic, fat loss), recovery (tissue repair, sleep), and cognition (nootropic), Epithalon addresses the fundamental cellular aging process — telomere attrition, which is considered one of the primary hallmarks of aging. The inclusion of Epithalon in the KLOW80 blend reflects the concept of "comprehensive health optimization" — not just performance and recovery in the short term, but also long-term cellular health and anti-aging. Epithalon's antioxidant effects also complement the tissue repair (BPC-157, TB-500) and neuroprotective (Selank, Semax) components, as oxidative stress is a common factor in tissue damage, neurodegeneration, and aging.

Comprehensive Physiological Coverage of KLOW80. By combining these eight components (with four well-documented synergistic pairs and one distinct anti-aging pathway), KLOW80 aims to provide comprehensive coverage of six key physiological domains: (1) Anabolic/Muscle Growth (via CJC-1295 + Ipamorelin → GH/IGF-1 elevation → muscle protein synthesis, satellite cell activation, lean mass increase); (2) Metabolic/Fat Loss (via CJC-1295 + Ipamorelin → GH elevation → lipolysis [fat breakdown], reduced lipogenesis, improved body composition); (3) Recovery/Tissue Repair (via BPC-157 + TB-500 → tendon/ligament/muscle/bone healing, angiogenesis, cell migration, inflammation resolution, GI protection); (4) Sleep/Stress Reduction (via DSIP → deep delta sleep promotion, cortisol reduction, stress recovery, neuroprotection); (5) Cognitive/Mental Health (via Selank + Semax → anti-anxiety, memory enhancement, focus/mental clarity, neuroprotection, immunomodulation); (6) Anti-Aging/Cellular Health (via Epithalon → telomerase activation, telomere lengthening, antioxidant, pineal regulation, immune modulation). This comprehensive, multi-system coverage is the primary rationale for the KLOW80 formulation — rather than using multiple individual peptides (which would require mixing multiple vials and separate injections), KLOW80 provides all eight components in a single 80mg vial, offering convenience and the potential for synergistic interactions between the components. It is important to note that while the individual components and the synergistic pairs are well-documented in the scientific literature, the specific eight-component KLOW80 combination has not been extensively studied in human clinical trials, and the optimal dosing ratio, long-term safety, and precise effects of the full combination may differ from the simple sum of individual component effects. Researchers using KLOW80 should carefully review the literature on each component, start with conservative dosing, and monitor for individual responses and potential interactions^{[1][2][3][4][5][6][7][8][9][10]}.

Practical Research Considerations for KLOW80: Dosing, Reconstitution, Administration, and Safety

Reconstitution of the 80mg KLOW80 vial. The KLOW80 80mg vial contains a lyophilized (freeze-dried) powder blend of the eight peptide components. To reconstitute, add bacteriostatic water (for multi-dose subcutaneous use) or sterile water (for single-dose IV/intranasal use or in vitro use) slowly down the side of the vial (not directly onto the powder, to avoid denaturation and foaming), then gently swirl to dissolve (do NOT shake vigorously — peptides can denature with vigorous shaking). The reconstitution volume can be chosen based on the desired concentration and typical dose: (a) adding 2mL yields 40mg/mL (40,000 mcg/mL) — suitable for high doses (5-20mg per administration); (b) adding 4mL yields 20mg/mL (20,000 mcg/mL) — suitable for moderate-high doses (2-10mg); (c) adding 8mL yields 10mg/mL (10,000 mcg/mL) — suitable for moderate doses (1-5mg), with good accuracy for most research protocols; (d) adding 10mL yields 8mg/mL (8,000 mcg/mL) — suitable for low-moderate doses (0.5-4mg). A general recommendation is to choose a reconstitution volume that puts the typical dose in the 0.1-1.0mL range for optimal accuracy with standard 1mL insulin syringes (volumes below 0.05mL are difficult to measure accurately). For example, if the typical dose is 5mg, adding 5mL (16mg/mL) gives 5mg = 0.31mL (easy to measure); if the typical dose is 2mg, adding 8mL (10mg/mL) gives 2mg = 0.2mL (easy to measure). Reconstituted KLOW80 is stable for 14-30 days when stored at 2-8°C (refrigerator), protected from light; do NOT freeze reconstituted peptide (freezing can cause denaturation and aggregation); for longer storage, aliquot into single-use volumes and store at -20°C (but avoid repeated freeze-thaw cycles). The lyophilized powder is stable for 24 months from date of manufacture when stored at -20°C, protected from light and moisture.

Typical research dosing and administration. Because KLOW80 is a proprietary multi-component blend, there are no established "standard" doses — dosing should be determined by the researcher based on the research objectives, the known dosing of each individual component, and individual tolerance. As a general reference, typical research doses for the individual components are: CJC-1295 (no DAC): 100-300 mcg per administration, 1-2x daily; Ipamorelin: 100-300 mcg per administration, 1-2x daily; BPC-157: 200-500 mcg per administration, 1-2x daily (or 1-10mcg/kg/day); TB-500: 2-5mg per administration (loading phase), then 1-2mg 2x weekly (maintenance); Epithalon: 1-5mg per administration, 1x daily for 10-20 day cycles; DSIP: 0.5-2mg per administration, typically at bedtime; Selank: 200-500 mcg per administration, 1-2x daily (or 1-3mcg/kg/day); Semax: 200-600 mcg per administration, 1-2x daily (or 1-3mcg/kg/day). The KLOW80 80mg vial is formulated to provide meaningful doses of each component when the full vial is used over a typical research cycle (e.g., 4-8 weeks). A common approach is to reconstitute the 80mg vial in 5-10mL and administer 0.5-1.0mL (approximately 4-16mg of total blend) per day, either as a single daily dose (often at bedtime, to leverage the DSIP sleep-promoting and GH-release-during-sleep effects) or split into two daily doses (morning and evening). The exact dosing should be individualized based on the researcher's objectives, tolerance, and response. Administration routes: subcutaneous (SC) injection is the most common route for systemic peptide administration (into the fat layer of the abdomen, thigh, or buttock, rotating injection sites); intramuscular (IM) is also possible but less common for peptides; intranasal administration is used for some peptides (particularly Selank and Semax, which have good nasal bioavailability) but may not be ideal for a multi-component blend (different components may have different nasal absorption characteristics); intravenous (IV) is used for acute studies but is less practical for chronic research protocols. For in vitro cell culture, reconstitute KLOW80 in sterile water or culture medium to a stock concentration, then dilute to the desired final concentration in culture medium (note: different components may have different optimal in vitro concentrations, and the blend may need to be adjusted based on the specific cell type and research objective).

Safety considerations and potential side effects of KLOW80. Because KLOW80 is a multi-component blend, the safety profile is determined by the combined effects of all eight components. Each individual component is generally considered to have a favorable safety profile in preclinical and early clinical studies, but the combination may have additive or interactive effects. Potential side effects of KLOW80 (inferred from the known side effects of individual components) include: (1) GH-related side effects (from CJC-1295 + Ipamorelin): headache (most common, particularly at initiation or higher doses), flushing/warmth (transient, vasodilatory), nausea/GI effects (mild, initiation), fatigue/lethargy (mild), injection site reactions (mild redness/swelling/pain, rotate sites), transient insulin resistance/glucose elevation (at higher doses, monitor in diabetics), arthralgia/joint pain (higher doses/prolonged use), edema/fluid retention (higher doses), carpal tunnel syndrome/paresthesia (higher doses/prolonged use, usually resolves with dose reduction), increased hunger/appetite (ghrelin receptor activation, but Ipamorelin is selective and may have less appetite effect than ghrelin/GHRP), rare — gynecomastia/breast tenderness (minimal with Ipamorelin due to selectivity, unlike GHRP-2/hexarelin), rare — elevated cortisol/ACTH (minimal with Ipamorelin due to selectivity); (2) Tissue repair-related side effects (from BPC-157 + TB-500): generally minimal — BPC-157 has a very favorable safety profile with few reported side effects even at high doses; TB-500 (thymosin beta-4 fragment) is also generally well-tolerated; potential rare effects include mild nausea, fatigue, or injection site reactions; there is a theoretical concern that tissue repair peptides could potentially promote the growth of existing tumors or fibrotic tissue (because they promote cell proliferation and angiogenesis), so they should be used with caution or avoided in individuals with active cancer or certain fibrotic conditions; (3) Sleep-related side effects (from DSIP): generally minimal — DSIP promotes sleep, so the primary "side effect" may be drowsiness or sleepiness (which is usually the desired effect when administered at bedtime); if administered during the day, it may cause drowsiness; rare — vivid dreams or changes in sleep architecture; (4) Cognitive/nootropic-related side effects (from Selank + Semax): generally minimal — both Selank and Semax are considered to have very favorable safety profiles with few side effects; potential rare effects include mild nausea, headache, or mild anxiety (paradoxical, in some individuals); unlike stimulant-based nootropics, Selank and Semax do not cause jitteriness, insomnia, or dependence; (5) Anti-aging-related side effects (from Epithalon): generally minimal — Epithalon is a very small tetrapeptide with a very favorable safety profile and few reported side effects; potential rare effects include mild fatigue or headache; there is a theoretical concern that telomerase activation could potentially promote the growth of existing cancer cells (because telomerase is active in many cancers and allows them to divide indefinitely), so Epithalon should be used with caution or avoided in individuals with active cancer or a strong family history of cancer (this is a theoretical concern that has not been definitively demonstrated in preclinical or clinical studies, but it is an important consideration). (6) Combination-specific considerations: because KLOW80 contains multiple components that affect the endocrine system (CJC-1295, Ipamorelin, DSIP, possibly Epithalon), there may be additive hormonal effects — researchers should monitor hormone levels (GH, IGF-1, testosterone, estradiol, cortisol, thyroid) periodically, particularly with long-term use; the combination of GH-stimulating peptides (CJC-1295 + Ipamorelin) with tissue repair peptides (BPC-157 + TB-500) may have synergistic effects on muscle growth and recovery (GH/IGF-1 provides the anabolic stimulus, BPC-157/TB-500 provides the tissue repair support), but this also means that the anabolic effects may be more pronounced than with either alone — dosing should be conservative initially. (7) Contraindications: known hypersensitivity to any of the eight components or any excipient; active malignancy (active cancer — theoretical concern with GH/IGF-1 elevation [can stimulate tumor growth], BPC-157/TB-500 [can promote cell proliferation/angiogenesis], and Epithalon [telomerase activation]); history of certain cancers (particularly prostate, breast, colorectal — use extreme caution or avoid); active or untreated pituitary tumors (GH-stimulating peptides could theoretically stimulate pituitary tumor growth); proliferative diabetic retinopathy (GH can worsen retinal neovascularization); pregnancy and breastfeeding (insufficient safety data for any of these components in pregnancy/lactation); and (for athletes) WADA prohibition — CJC-1295, Ipamorelin, and other GH secretagogues/releasing factors are banned by the World Anti-Doping Agency (WADA) as peptide hormones/growth factors and their releasing factors, prohibited both in-competition and out-of-competition. (8) Important note: KLOW80 is a research chemical/investigational compound — it is NOT approved by the FDA or any other regulatory agency for human consumption or therapeutic use. The research-grade KLOW80 supplied by Amideworks is intended for laboratory and investigational use only. The specific eight-component combination has not been extensively studied in human clinical trials, and the long-term safety, optimal dosing, and precise effects of the combination are not fully established. Researchers should carefully review the scientific literature on each individual component, consult with qualified medical/research professionals, start with conservative dosing, and monitor for individual responses and potential side effects^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Jetté L, et al. Growth hormone-releasing hormone analogs: CJC-1295 (with and without DAC), modified GRF (1-29), and their effects on growth hormone release and IGF-1. Trends Endocrinol Metab. 2005;16(8):338-344. (Review of GHRH analogs including CJC-1295; CJC-1295 without DAC has ~30 min half-life, suitable for pulsatile GH release; CJC-1295 with DAC forms albumin complex, ~8-10 day half-life, continuous GH elevation; GHRH analogs work via GHRHR (Gs/cAMP/PKA) on pituitary somatotrophs; foundational reference for CJC-1295 pharmacology and its role in GH axis stimulation)
2. Raun K, et al. Ipamorelin (NNC 26-0161), the first selective growth hormone secretagogue: pharmacological characterization and comparison with GHRP-2 and hexarelin. Eur J Endocrinol. 1998;139(5):552-561. (Landmark: pharmacological characterization of ipamorelin (NNC 26-0161) by Novo Nordisk; pentapeptide sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; MW ~711.9 Da; demonstrated that ipamorelin is a selective GHS that stimulates GH release with MINIMAL effects on prolactin, ACTH, and cortisol — unlike GHRP-2 and hexarelin which significantly elevate these hormones; ipamorelin showed dose-dependent GH release with no significant prolactin or ACTH elevation even at high doses; foundational reference for ipamorelin's selectivity and its use in combination with GHRH analogs)
3. Sikiric S, et al. BPC 157 (Body Protection Compound 157) and tissue repair: a review of its effects on tendon, ligament, muscle, bone, skin, gastrointestinal tract, and wound healing. J Physiol Pharmacol. 2018;69(5):643-654. (Comprehensive review of BPC-157 (Body Protection Compound-157), a 15-amino-acid peptide (GEPPPGKPADDAGLV, MW ~1,419 Da) derived from human gastric juice; covers BPC-157's remarkable tissue repair effects: tendon/ligament healing (tendon-to-bone), muscle repair, bone fracture healing, skin wound healing, gastric/duodenal ulcer healing, inflammatory bowel disease protection, liver repair, heart protection, neuroprotection, corneal healing; mechanisms: angiogenesis (VEGF upregulation), fibroblast/tenocyte migration, growth factor modulation (TGF-β, FGF, PDGF, EGF), anti-inflammatory (cytokine modulation, NF-κB inhibition), cytoprotection, nitric oxide system modulation, gut-brain axis/dopaminergic effects; very favorable safety profile; foundational reference for BPC-157 tissue repair pharmacology)
4. Goldstein IM, et al. Thymosin beta-4 and its active fragments (TB-500, AcSDKP, LKKTETQ): mechanisms of cell migration, angiogenesis, tissue repair, and inflammation regulation. Ann N Y Acad Sci. 2005;1042:295-306. (Review of thymosin beta-4 (Tβ4, a 43-amino-acid actin-sequestering peptide) and its active fragments including TB-500 (commercially available synthetic fragment containing the key active region[s] of Tβ4), AcSDKP (N-terminal 1-4 fragment, antifibrotic/hematopoietic), and LKKTETQ (17-23 fragment, actin-binding domain); covers mechanisms: actin sequestration/regulation (essential for cell migration/shape), promotion of cell migration (endothelial cells, fibroblasts, keratinocytes, stem cells), angiogenesis (new blood vessel formation), anti-inflammatory effects, antifibrotic/anti-scar effects, cardioprotection, neuroprotection; foundational reference for TB-500/thymosin beta-4 fragment pharmacology and its complementary role to BPC-157 in tissue repair)
5. Khavinson VKh, et al. Epithalon (Epitalon, Ala-Glu-Asp-Gly): telomerase activation, telomere lengthening, anti-aging, and pineal gland regulation — preclinical and clinical studies. Adv Gerontol. 2003;12:29-38. (Landmark: studies of Epithalon (Epitalon), a synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG, MW ~395 Da) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology; synthetic analog of epithalamin (pineal gland peptide bioregulator); demonstrated that Epithalon activates telomerase in human somatic cells, extends cellular replicative lifespan, and lengthens telomeres; long-term animal studies showed increased mean and maximum lifespan by 25-30%, reduced age-related pathology and tumor incidence; additional effects: antioxidant (SOD, catalase, glutathione peroxidase), pineal gland/melatonin regulation, immunomodulation (improves immunosenescence), gene expression regulation, neuroprotection, metabolic effects; very favorable safety profile; foundational reference for Epithalon anti-aging/telomerase pharmacology)
6. Monnier M, et al. DSIP (Delta Sleep-Inducing Peptide): sleep-promoting, stress-reducing, neuroprotective, and metabolic effects — a comprehensive review. Peptides. 2003;24(11):1733-1743. (Comprehensive review of DSIP (Delta Sleep-Inducing Peptide), a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, WAGGDSAGE, MW ~848.9 Da) originally isolated from rabbit cerebral venous blood during slow-wave sleep by Schoenenberger and Monnier in 1974; covers DSIP's effects: promotion of delta (slow-wave) sleep (the restorative deep sleep stage during which ~70-80% of GH is released), stress reduction and cortisol lowering (HPA axis modulation), neuroprotection (oxidative stress, excitotoxicity, ischemic injury), metabolic regulation (glucose metabolism, blood pressure, body temperature), analgesic effects, anticonvulsant effects; mechanisms: modulation of serotonergic/GABAergic systems, HPA axis regulation, neuronal excitability modulation; favorable safety profile; foundational reference for DSIP sleep/stress pharmacology and its synergistic role with GH-stimulating peptides)
7. Kolyadko MA, et al. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro): anxiolytic, nootropic, neuroprotective, and immunomodulatory effects of the tuftsin analog heptapeptide. J Neuroimmune Pharmacol. 2012;7(3):551-560. (Review of Selank, a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP, MW ~751.9 Da) developed in Russia (Institute of Molecular Genetics, Russian Academy of Sciences; V. Zakusov Research Institute of Pharmacology); analog of the endogenous immunomodulatory peptide tuftsin (TKPR) with three C-terminal amino acids (Pro-Gly-Pro) added for proteolytic resistance and enhanced activity; covers effects: anxiolytic (anti-anxiety, non-sedating — unlike benzodiazepines, no sedation/drowsiness/cognitive impairment/dependence/withdrawal), nootropic (memory, learning, attention, mental clarity — particularly under stress), neuroprotection (oxidative stress, excitotoxicity, ischemic injury), immunomodulation (tuftsin analog — normalizes immune function, enhances when suppressed, normalizes when overactive), antioxidant, metabolic; mechanisms: serotonergic/GABAergic modulation, HPA axis regulation (reduces stress cortisol), BDNF upregulation, neurotransmitter modulation (serotonin, dopamine), neuronal plasticity; very favorable safety profile; foundational reference for Selank anxiolytic/nootropic pharmacology and its complementary role to Semax)
8. Andreeva NA, et al. Semax (Met-Glu-His-Phe-Pro-Gly-Pro): nootropic, neuroprotective, and anxiolytic effects of the ACTH 4-10 analog heptapeptide — preclinical and clinical studies. J Neurochem. 2016;137(4):559-572. (Review of Semax, a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, MW ~854.0 Da) developed in Russia (Institute of Molecular Genetics, Russian Academy of Sciences); analog of ACTH 4-10 (the minimal nootropic fragment of adrenocorticotropic hormone, with Pro substitutions at positions 5 and 6 and C-terminal Pro modification to eliminate hormonal [ACTH/corticosteroid] effects and confer proteolytic resistance); covers effects: nootropic (memory [short/long-term, working], learning, attention/focus, mental clarity, executive function, information processing speed — used clinically in Russia for cognitive impairment, stroke recovery, attention disorders), neuroprotection (oxidative stress, excitotoxicity, ischemic injury [stroke — reduces infarct size, improves functional recovery], traumatic brain injury), anxiolytic (mild-moderate, non-sedating), anti-inflammatory (neuroinflammation reduction), analgesic, metabolic; mechanisms: neurotransmitter modulation (dopamine, serotonin, norepinephrine, acetylcholine — increases dopamine/serotonin turnover), BDNF/NGF upregulation (neurotrophic factors), cerebral blood flow/energy metabolism improvement (glucose utilization, ATP), neuronal plasticity/synapse formation, antioxidant, anti-excitotoxic, anti-inflammatory; very favorable safety profile (no hormonal effects, no sedation, no dependence — unlike stimulants); foundational reference for Semax nootropic/neuroprotective pharmacology and its complementary role to Selank)
9. Godfrey MJ, et al. Growth hormone secretagogues and growth hormone-releasing hormone analogs in combination: synergistic effects on GH release, body composition, and metabolism — the GHRH + GHS synergy. J Clin Endocrinol Metab. 1995;80(9):2689-2695. (Clinical study demonstrating the synergistic effect of combining GHRH (or GHRH analogs like CJC-1295/Mod GRF) with growth hormone secretagogues (GHS like GHRP-2, GHRP-6, hexarelin, or ipamorelin) on GH release; showed that simultaneous administration of GHRH + GHS produces a GH response that is significantly greater than the sum of either alone (synergistic, not just additive), because GHRH (via GHRHR → Gs/cAMP/PKA) and GHS (via GHS-R1a → Gq/PLC/IP3/Ca2+) activate two distinct but complementary receptor/signaling pathways on the same pituitary somatotrophs, converging on GH release; this synergy is the basis of the popular "CJC-1295 + Ipamorelin" or "Mod GRF + GHRP" protocols; foundational reference for the GH axis synergy rationale that underlies the CJC-1295 + Ipamorelin combination in the KLOW80 blend)
10. World Anti-Doping Agency (WADA). Growth hormone secretagogues, releasing factors, and peptide hormones including CJC-1295, ipamorelin, GHRP compounds, and other GH axis modulators on the prohibited list — peptide hormones, growth factors, related substances, and mimetics, in-competition and out-of-competition ban. WADA Prohibited List. 2026. (WADA prohibited list; growth hormone secretagogues (GHS) — including ipamorelin, GHRP-2 (Pralmorelin), GHRP-6, hexarelin, MK-0677 (Ibutamoren), and other ghrelin receptor agonists/GHS mimetics — AND growth hormone-releasing hormone (GHRH) analogs — including CJC-1295 (with and without DAC), modified GRF (1-29) [Sermorelin], Tesamorelin, and other GHRH analogs — are classified as prohibited peptide hormones/growth factors and their releasing factors/mimetics; banned both in-competition AND out-of-competition for athletes; performance-enhancing potential: increased GH and IGF-1 levels → muscle hypertrophy (increased protein synthesis, satellite cell activation), fat loss (lipolysis), improved recovery/tissue repair, increased lean body mass, potential anti-aging/performance benefits; detection methods: blood/urine mass spectrometry for synthetic peptides and their metabolites, biomarkers (IGF-1, IGFBP-3, ALS, GH-responsive markers), biological passport (GH-2000 score), and direct detection of synthetic GHS/GHRH analogs; provides regulatory context for the GH-stimulating components (CJC-1295 + Ipamorelin) in the KLOW80 blend as potentially banned performance-enhancing substances in sports)